First-line immunotherapy in advanced non-small-cell lung cancer

被引：0
|
作者：
Noronha, Vanita [1 ]
Mehta, Prashant [2 ]
Malik, Prabhat Singh [3 ]
Patel, Amol [4 ]
机构：
[1] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[2] Asian Inst Med Sci, Dept Med Oncol Hematol BMT, Faridabad, Haryana, India
[3] All India Inst Med Sci, Dept Med Oncol, New Delhi, India
[4] Army Hosp Res & Referral, Malignant Dis Treatment Ctr, New Delhi, India
来源：
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2019年 / 40卷 / 04期
关键词：
D O I：
10.4103/ijmpo.ijmpo_210_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [1] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
    Reck, Martin
    Remon, Jordi
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
  • [2] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [3] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [4] Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer
    Heigener, David F.
    Kerr, Keith M.
    Laing, Gavin M.
    Mok, Tony S. K.
    Moiseyenko, Fedor V.
    Reck, Martin
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4881 - 4887
  • [5] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [6] Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
    Socinski, M. A.
    [J]. CURRENT ONCOLOGY, 2014, 21 (05) : E691 - E703
  • [7] PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients
    Schulze, Arik Bernard
    Schmidt, Lars Henning
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (04) : E384 - E386
  • [8] How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
    Peters, S.
    Reck, M.
    Smit, E. F.
    Mok, T.
    Hellmann, M. D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (06) : 884 - 896
  • [9] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
    不详
    [J]. ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
  • [10] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
12345